CD8A and neoplasm: FCM results depicted that the ratio of tumor-infiltrating CD8+ T/Treg was 4.6 for the ULNPs-cRNAIL-2F@LG + αPD-L1 treatment, which was much higher than those of ULNPs-cRNAIL-2F@LG (2.3) and αPD-L1 (1.2) therapies, indicating an enhanced antitumor immunity (Fig. 6G).